Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Onward Medical N.V.

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. 

ONWARD Medical has received nine Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed its first-in-human use of the ARC-IM neurostimulator in May 2022. 

ONWARD Medical is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). 

ONWARD

🎉 Congratulations to our Vice President, Clinical, Regulatory, & Quality, Dr. Erika Ross Ellison, for her recent election as President of the Institute of Electrical and Electronics Engineers IEEE Engineering in Medicine and Biology Society (EMBS), the world’s largest international society of biomedical engineers. 
 
We proudly celebrate Erika’s historic achievement. Her election marks the first time in the 72-year history of IEEE EMBS that a leader from industry will serve in this volunteer position. Erika will be the 7th woman in the society’s history to lead the organization. 
 
IEEE EMBS is driven by a mission to create innovations in healthcare technology for the benefit of all humanity. The group’s 12,000 members span 97 countries and include #researchers, #educators, #engineers and #clinicans. Their areas of expertise run wide and deep, including medical technology, #bioinformatics, #biotechnology, #robots. Many are also focused on the translation of science to clinical practice.  
 
We also celebrate this moment as an opportunity to further collaborate across the intersection of health and technology. As a company dedicated to developing groundbreaking solutions to serve the spinal cord injury (SCI) Community, having visibility and access to the most cutting-edge resources and talent is a true honor.  
 
Way to go, Erika! 🎉 
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

#EmpoweringMovement #SCI

Looking forward to participating in BioCapital Europe in Amsterdam TODAY! 

The event, one of Europe’s leading life sciences investor conferences, is organized by venture capital fund EQT Group, an investor in our company.

During the conference, CEO Dave Marver will present and participate in 1:1 and group meetings with investors to discuss the Company’s leadership in neuroscience, including the use of our investigational ONWARD ARC-IM® Therapy paired with brain-computer interface (BCI) technology.  
  
Tickets are sold out, but we encourage you to watch the livestream by clicking on the link below to learn more about the latest advances in #medtech, #therapeutics, and #neuroscience. Don’t miss our presentation at 11:20 am CET today. 
 
#EmpoweringMovement #SCI #Innovation #BioCapitalEurope
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
https://lnkd.in/gJNc-2qG


“There is no protocol for this. You must figure it out every day...” 
 
Kevin Babington, a former Olympian and equestrian champion with an SCI, and his wife Dianna recently shared a glimpse into their daily lives with our ONWARD team. Kevin had just experienced a medical setback and the resulting emotions were clear in our candid conversation about the struggles for people living with spinal cord injury.
 
Dianna openly shared how their lives have changed since Kevin’s injury during the 2019 Hampton Classic Horse Show. “There is no more cuddling on the couch, no spontaneous trips…it is everyday grinding, even with all the support that we have found within our community.” Dianna’s testimony was gripping and demonstrated a deep vulnerability that both moved and motivated us. 
 
Despite their challenges, Kevin and Dianna are optimistic things will get better and said they are cheering for companies like ONWARD that are dedicated to making new solutions a reality. Read more about the Babington’s work to bring hope to other equestrians with SCI through the The Kevin Babington Foundation.
 
*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
#EmpoweringMovement #SCI

✨ Thanks to De 7, the podcast from Belgian newspaper De Tijd, for its deep dive on brain-computer interface (BCI) technology. The episode, which was in Dutch, examined the buzz behind last week’s news about Neuralink’s first human implant, what it means, and the opportunities for investors. 
 
The show also laid out the events leading up to the news, and noted “this is not a first, the Dutch company ONWARD already implanted one [BCI] several years ago.” 

Education around new scientific breakthroughs is vital to continue progress and prevent misinformation. We appreciate journalists who help the public learn more about this groundbreaking investigational technology that has the potential to be used in combination with our investigational ARC Therapy™ to improve the lives of those with spinal cord injuries or other movement disorders. 

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

#EmpoweringMovement #BCI #SCI

It was a pleasure to participate in the Degroof Petercam Healthcare Conference this month, where our CEO Dave Marver updated attendees on our progress to launch ARC-EX® later this year. 
 
Thank you to all who joined us. You are critical for our mission to provide innovative solutions to restore movement, function, and independence after spinal cord injury (SCI).

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
  
#EmpoweringMovement #SCI #Investors

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory
average payables		600K -	1.08M 79.83%	1.11M 2.73%	931.50K 15.97%	1.43M 53.57%
average receivables
book value per share		-1.74 -	-2.53 45.32%	-5.44 115.07%	8.72 260.25%	1.74 80.00%
capex per share		-0.02 -	-0.02 20.39%	-0.03 39.52%	-0.25 735.61%	-0.01 94.36%
capex to depreciation		-0.44 -	-0.54 23.02%	-0.64 17.89%	-7.06 1,006.53%	-0.57 91.97%
capex to operating cash flow		0.01 -	0.01 12.49%	0.01 6.47%	0.12 772.02%	0.02 86.64%
capex to revenue
cash per share		1.47 -	2.56 74.60%	1.08 57.82%	9.43 771.77%	2.05 78.30%
days of inventory on hand
days payables outstanding		298.73 -	568.84 90.42%	144.01 74.68%	85.86 40.38%	47.44 44.75%
days sales outstanding
debt to assets	1.30 -	1.84 40.99%	1.45 21.18%	2.96 104.48%	0.13 95.60%	0.19 43.95%
debt to equity	-2.74 -	-1.71 37.57%	-2.27 32.44%	-1.31 42.21%	0.17 112.62%	0.27 65.28%
dividend yield
earnings yield		-0.13 -	-0.18 36.03%	-0.27 48.44%	-0.35 33.21%	-0.17 50.78%
enterprise value	3.39M -	84.06M 2,380.50%	93.84M 11.63%	110.80M 18.07%	20.97M 81.07%	160.36M 664.76%
enterprise value over ebitda		-10.29 -	-8.90 13.47%	-7.25 18.59%	-0.74 89.78%	-5.13 592.19%
ev to operating cash flow		-11.75 -	-9.53 18.86%	-8.59 9.90%	-1.06 87.71%	-6.01 469.56%
ev to sales
free cash flow per share		-1.23 -	-1.69 37.33%	-2.22 31.15%	-2.34 5.61%	-0.90 61.63%
free cash flow yield		-0.10 -	-0.13 37.33%	-0.17 31.15%	-0.23 31.91%	-0.14 37.08%
graham net net		-1.89 -	-3.92 107.26%	-6.76 72.45%	7.10 204.96%	1.25 82.36%
graham number		8.11 -	11.40 40.60%	20.38 78.68%	26.64 30.73%	6.53 75.50%
income quality		0.72 -	0.73 1.25%	0.65 11.89%	0.58 10.06%	0.80 37.10%
intangibles to total assets	0.01 -	0.00 53.48%	0.32 11,992.00%	0.48 52.10%	0.10 80.10%	0.13 38.58%	0 100%
interest coverage		-5.65 -	-4.03 28.65%	-3.50 13.18%	-5.10 45.58%	-21.14 314.71%	-59.17 179.87%
interest debt per share		3.23 -	6.18 91.46%	7.87 27.34%	2.03 74.20%	0.53 74.07%
inventory turnover
invested capital	-2.74 -	-1.71 37.57%	-2.27 32.44%	-1.31 42.21%	0.17 112.62%	0.27 65.28%
market cap		75.17M -	75.17M 0%	75.17M 0%	96.75M 28.71%	187.74M 94.06%
net current asset value	-4.59M -	-10.83M 136.12%	-22.77M 110.23%	-39.32M 72.64%	70.27M 278.74%	40.21M 42.78%
net debt to ebitda		-1.09 -	-1.77 62.68%	-2.33 31.56%	2.68 214.84%	0.88 67.29%
net income per share		-1.68 -	-2.29 36.03%	-3.39 48.44%	-3.62 6.65%	-1.09 69.99%
operating cash flow per share		-1.21 -	-1.67 37.58%	-2.19 31.04%	-2.10 4.18%	-0.88 57.81%
payables turnover		1.22 -	0.64 47.48%	2.53 295.01%	4.25 67.72%	7.69 80.98%
receivables turnover
research and ddevelopement to revenue
return on tangible assets		-1.04 -	-0.84 18.75%	-2.72 221.73%	-0.36 86.68%	-0.49 36.24%
revenue per share
roe		0.97 -	0.90 6.40%	0.62 30.98%	-0.42 166.55%	-0.62 50.04%
roic		-1.09 -	-0.56 48.47%	-1.53 172.80%	-0.29 81.10%	-0.46 56.99%
sales general and administrative to revenue
shareholders equity per share		-1.74 -	-2.53 45.32%	-5.44 115.07%	8.72 260.25%	1.74 80.00%
stock based compensation to revenue
tangible asset value	-3.94M -	-10.29M 161.40%	-22.30M 116.68%	-38.92M 74.49%	72.65M 286.68%	42.47M 41.54%
tangible book value per share		-1.74 -	-3.78 116.68%	-6.60 74.49%	7.66 216.12%	1.41 81.63%
working capital	6.35M -	6.99M 10.09%	12.78M 82.81%	4.30M 66.33%	86.84M 1,918.24%	55.95M 35.57%

COM:ONWD

Wuhan Donglisheng M&E Technology Co., LTD

Last Close

4.66

22/11 16:35

Market Cap

179.38M

Beta: -

Volume Today

59.94K

Avg: -

Preview